Search

Your search keyword '"Rascol, Olivier"' showing total 18 results
Start Over Author "Rascol, Olivier" Journal clinical neuropharmacology
18 results on '"Rascol, Olivier"'

2. Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease

Author

Mizuno, Yoshikuni, primary, Yamamoto, Mitsutoshi, additional, Kuno, Sadako, additional, Hasegawa, Kazuko, additional, Hattori, Nobutaka, additional, Kagimura, Tatsuro, additional, Sarashina, Akiko, additional, Rascol, Olivier, additional, Schapira, Anthony H.V., additional, Barone, Paolo, additional, Hauser, Robert A., additional, and Poewe, Werner, additional

Published
2012
Full Text
View/download PDF

3. Perampanel in Parkinson Disease Fluctuations

Author

Rascol, Olivier, primary, Barone, Paolo, additional, Behari, Madhuri, additional, Emre, Murat, additional, Giladi, Nir, additional, Olanow, C. Warren, additional, Ruzicka, Evzen, additional, Bibbiani, Francesco, additional, Squillacote, David, additional, Patten, Anna, additional, and Tolosa, Eduardo, additional

Published
2012
Full Text
View/download PDF

4. Pergolide

Author

Thalamas, Claire, primary, Rajman, Iris, additional, Kulisevsky, Jaime, additional, Lledó, Alberto, additional, Mackie, Alison E, additional, Blin, Olivier, additional, Gillespie, Todd A, additional, Seger, Mary, additional, and Rascol, Olivier, additional

Published
2005
Full Text
View/download PDF

10. L-Dopa-Induced Sedation

Author

Andreu, Nathalie, primary, Chalé, Jean-Jacques, additional, Senard, Jean-Michel, additional, Thalamas, Claire, additional, Montastruc, Jean-Louis, additional, and Rascol, Olivier, additional

Published
1999
Full Text
View/download PDF

18. Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease.

Author

Thalamas C, Rajman I, Kulisevsky J, Lledó A, Mackie AE, Blin O, Gillespie TA, Seger M, and Rascol O

Subjects
Aged, Antiparkinson Agents therapeutic use, Area Under Curve, Dose-Response Relationship, Drug, Female, Half-Life, Humans, Male, Middle Aged, Movement, Parkinson Disease drug therapy, Parkinson Disease physiopathology, Pergolide therapeutic use, Antiparkinson Agents administration & dosage, Antiparkinson Agents pharmacokinetics, Parkinson Disease metabolism, Pergolide administration & dosage, Pergolide pharmacokinetics
Abstract

The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and efficacy. Fourteen patients with a diagnosis of Parkinson disease completed this multicenter, open-label, dose-escalating study. Pergolide was administered for 58 days, using increasing daily doses from 0.05 mg daily up to 1 mg three times daily and then tapering the dose. The steady-state pharmacokinetic profile and motor score were determined at dose levels of 0.25, 0.5, and 1 mg three times a day and during elimination after the last dose. Pergolide was absorbed with a median time to maximum concentration of 2 to 3 hours across the dose range. Systemic exposure appeared to increase proportionally with dose over the range of 0.25 to 1 mg three times daily within a patient, but there was a large variability in exposures between patients (interpatient coefficients of variation were 56.4% for the area under the curve). Pergolide was widely distributed (volume of distribution, approximately 14,000 L) and was eliminated with a mean half-life of 21 hours. Motor scores improved as both peak plasma pergolide concentrations and exposure increased. No unexpected safety concerns were identified. Pergolide is absorbed relatively quickly into the systemic circulation, has a large apparent volume of distribution, and has a relatively long half-life (mean, 21 hours). This prolonged half-life is of particular interest, given the current hypothesis that more continuous dopaminergic receptor stimulation may reduce motor complications in patients with Parkinson disease.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results